Gland Pharma Limited has provided a crucial clarification regarding the reappointment of Ms. Naina Lal Kidwai as an Independent Director. The company confirms that for any financial year between FY 2026-27 and FY 2030-31 where her remuneration exceeds 50% of the total payout to all Non-Executive Directors, the company will seek specific approval from its members via a special resolution.
Commitment to Transparent Governance
Following the initial postal ballot notice issued on April 9, 2026, Gland Pharma Limited has released a formal clarification to ensure complete transparency regarding the compensation structure for its leadership. The company is committed to maintaining high standards of corporate governance by ensuring that significant remuneration decisions remain subject to shareholder oversight.
Shareholder Oversight Mechanism
The company has established a rigorous framework for the upcoming five-year period, spanning from FY 2026-27 to FY 2030-31. Under this policy, whenever the remuneration payable to Ms. Naina Lal Kidwai is projected to exceed 50% of the aggregate remuneration designated for all Non-Executive Directors, the company is mandated to obtain explicit approval from its members.
This process will be conducted through a special resolution in each applicable financial year, ensuring that shareholders have the final say on substantial remuneration disbursements.
Source: BSE
